JW0104+C2402 / JW Pharma - LARVOL DELTA

To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: JW Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia (clinicaltrials.gov) - P3 | N=162 | Recruiting | Sponsor: JW Pharmaceutical | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: JW Pharmaceutical

New P1 trial